CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 140 enrolled
Drug / intervention
fluoxetinedrug
Likely dose
fluoxetine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01075529
NCT01075529Phase 4Completed
CompareCT.gov

Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine

Kaohsiung Kai-Suan Psychiatric Hospital·interventional·Posted Feb 25, 2010·Updated Feb 25, 2010

In Brief

A Phase 4 clinical trial evaluating fluoxetine for Major Depressive Disorder. Completed, enrolled 140 participants across 1 site.

Detailed Summary

The purpose of this study is to identify what degree of symptom changes during the early weeks could be used to predict eventual nonresponse at week 6 among depressive inpatients taking fluoxetine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesTaiwan
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 25, 2010
Enrollment StartMar 1, 2007
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.4 years ago

Interventions

fluoxetinedrug

fluoxetine 20 mg/d